Accelerating early clinical development through integrated academic expertise and state-of-the-art patient care

The Collaborative Phase I Unit is operated by the Krankenhaus Nordwest and provides a highly specialized environment for early clinical drug development. Embedded within one of Germany’s leading oncology centers and closely linked to the University Cancer Center Frankfurt (UCT Frankfurt), the unit combines comprehensive clinical care, translational expertise, and access to a broad population of patients with advanced malignancies.

The unit focuses on phase I and early phase clinical trials, including first-in-human studies, novel targeted therapies, immunotherapies, antibody-drug conjugates, cellular therapies, and innovative combination strategies. Its close interaction with the Frankfurt Institute of Clinical Cancer Research IKF enables seamless integration of scientific concepts, clinical operations, biomarker programs, and patient recruitment.

A particular strength of the Collaborative Phase I Unit is its integration into a full-service oncology environment, allowing rapid clinical evaluation of new compounds while maintaining the highest standards of patient safety and scientific quality. The unit benefits from experienced investigators, multidisciplinary tumor boards, molecular diagnostics, and access to extensive national and international clinical trial networks.

Together, the Collaborative Phase I Unit of Krankenhaus Nordwest and IKF create a unique ecosystem where innovative academic concepts and biotech-driven drug development can be translated efficiently into clinical reality.